| Literature DB >> 26726970 |
Li-Hua Dong1, Li-Juan Zhang1,2, Wen-Jia Wang1, Wen Lei1, Xing Sun1, Jian-Wei Du1, Xue Gao1, Gang-Ping Li1, Yu-Fu Li1.
Abstract
Extranodal natural killer (NK)/T-cell lymphoma is an aggressive lymphoid tumor. Optimal treatment strategies have not yet been fully defined. To explore a more effective treatment, we conducted sequential chemoradiotherapy (SCRT) and evaluated the safety and efficacy. Seventy-eight patients (51 males, 27 females) were analyzed. The complete response (CR) rate was higher for patients in the SCRT group (90.9%) than in the radiotherapy group (77.8%; p = 0.124). The relapse rate (RR) and death rate (DR) were lower in the SCRT group (RR: 6.7% vs 33.3%, p < 0.001; DR: 15.2% vs. 55.6%, p < 0.001). Progression-free survival (PFS) and overall survival (OS) rates of 5 years after diagnosis were significantly higher for patients in the SCRT group (PFS: 89%; OS: 82%) than in the radiotherapy group (PFS: 49%, p < 0.001; OS: 49%, p < 0.001). Treatment-related adverse events were more common in the SCRT group. However, the adverse events were controlled.Entities:
Keywords: DICE regimen; l-asparaginase; nasal natural killer/T-cell lymphoma treatment
Mesh:
Substances:
Year: 2016 PMID: 26726970 DOI: 10.3109/10428194.2015.1108415
Source DB: PubMed Journal: Leuk Lymphoma ISSN: 1026-8022